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ABSTRACT 
Background: Obesity, a growing health crisis in the United States, is an independent risk 
factor for increased morbidity and mortality from infection with influenza. Annual 
vaccination is the preferred strategy to prevent infection with influenza virus, but obesity 
is associated with decreased protective antibody titer against influenza compared to that 
of healthy-weight individuals post-vaccination. No previous studies have compared the 
immune response to influenza vaccine with duration of obesity.  
 
Objective: This study employed a sample of twenty short-term obese individuals and 
twenty long-term obese individuals to determine the IgG antibody response to the 2014-
15 inactivated trivalent influenza vaccine pre-vaccination and thirty days post-
vaccination. 
 
Results: There was no significant difference in mean IgG 1, 2 or total IgG antibody titer 
for short term obese and long term obese individuals as detected by ELISA. However, 
long-term obese individuals did have a higher IgG 2 antibody titer than did short-term 
obese individuals. Additionally, the youngest, long-term obese individuals had the lowest 
pre-vaccination IgG 1 and IgG Total antibody titers, which started higher and negatively 
correlated with age for short term obese individuals pre- and post-vaccination as well as 
long-term obese individuals post-vaccination (Figures 4 and 6).  
 
Conclusions: While we did not find differences in immune response to influenza 
vaccination as measured by IgG antibody titer due to duration of obesity, these data that 
the age of obesity onset may have an effect on immune response to influenza vaccination. 
 
INTRODUCTION 
The annual burden of influenza in the United States is estimated to be 25-30 million 
cases, leading to 30,000-40,000 deaths.1 Approximately 10-20% of the population in 
developed countries is infected during influenza epidemics each year. Additionally, 
obesity is creating an additional health burden in the United States, with 34.9% of adults 
suffering from obesity in the US in 20152, as well as 42 million obese children under the 
age of 5 in the US in 2013.3  
 
Obesity related conditions such as heart disease, type 2 diabetes, and some types of 
cancer have become some of the leading causes of preventable death in the US, and 
obesity itself is suggested to impair immunity in obese patients infected with pandemic 
H1N1 influenza.4 
 
Annual influenza vaccination is the preferred strategy for decreasing the risk of infection 
with influenza virus. In 2011, Sheridan et al. examined the immune response to influenza 
vaccination among healthy weight and obese humans, becoming the first study to suggest 
that obesity may negatively affect human immune response to influenza vaccine.5 
Another study found that obese children had lower anti-tetanus IgG antibodies when 
compared to age-matched healthy weight controls, providing additional evidence of 
obesity-related impairment of the immune response.6 Mechanistically, over-nutrition 
increases anabolic hormones, including insulin and IGF-1 in the body. mTOR integrates 
these hormonal inputs from metabolic pathways and senses cellular nutrient content, but 
the mTOR pathway is dysregulated and continuously activated in obesity, which is a 
chronic state of over-nutrition in the most basic sense. Disrupted mTOR signaling and 
mitochondrial dysfunction increases cytokine production and decreases B and T cell 
proliferation, reducing the effectiveness of an immune response.7  
 
Based on this prior research, I chose to compare individuals who had been obese for more 
than ten years with other individuals, who had been obese for less than ten years and 
were matched for age, BMI, and diabetic and smoking status to see if the duration of 
obesity and chronic over-nutrition further impaired the immune response to influenza 
vaccine compared to the simple presence of obesity. I chose ten years as the cut point for 
long term obesity because I hypothesized that it would be a reasonably long amount of 
time for the immune system to exhibit any obesity-fueled changes and because it was also 
a reasonable amount of time to allow me to find regular and continuous evidence of 
obesity over a period of ten years in the patient medical records. A longer cut-point for 
long term obesity would have been unfeasible for this study because many patients at the 
UNC Family Medicine Center did not have significantly more than ten years of data in 
their medical records. I, therefore, designed and carried out a small study using serum 
samples from 40 participants in the fifth year (2014-2015) of the same population as the 
Beck clinical research population.  
 
I hypothesized that individuals who have been obese for ten years or longer would have a 
decreased immune response to influenza vaccine than would obese individuals who have 
been obese for less than ten years, as measured by influenza specific IgG antibodies 
detected by ELISA. 
 
METHODS 
Study design and subjects 
This study was carried out at the University of North Carolina at Chapel Hill. The 
subjects were part of an ongoing, prospective observational study being conducted at the 
University of North Carolina Family Medicine Center. Forty participants who received 
the 2014-2015 seasonal trivalent influenza vaccine were selected post-collection for this 
analysis based on medical record data. 
 
The 40 subjects were selected based on one of two criteria: The first was classified as 
“Short Term Obese (STO)” and consisted of subjects whose medical records showed a 
BMI change from healthy weight (BMI 18.5 ≤ 24.9) or overweight (BMI 25 ≤ 29.9) to 
obese (BMI > 30.0) within the last 10 years. The second group was classified as “Long 
Term Obese (LTO)” and consisted of subjects who had been medically obese (BMI > 
30.0) for at least ten years, as verified by medical records. The 20 subjects in the two 
groups were matched based on sex, race, diabetic status, age, and BMI.  
 
 
 
Table 1: Overall Demographic Data of Study Participants 
 
Table 2: Demographic Characteristics of Each Study Participant 
 
 
ELISA 
Immune response was quantified using enzyme linked immunosorbent assay (ELISA) 
and pre- and post-vaccination serum samples from each subject. IgG antibodies were 
quantified by ELISA, using the 2014-2015 trivalent influenza vaccine as antigen. 
Vaccine was diluted in PBS coating buffer, added to plates, and allowed to sit overnight 
in order for vaccine antigens to bind to the plate wells. Blocking buffer was then applied 
to plates and allowed to incubate for one hour to coat the plate wells and prevent any 
antibodies from binding nonspecifically to the well walls. After plates were washed, 
serum samples were diluted in a solution of nonfat milk and PBS and were plated and 
allowed to bind vaccine antigen. The quantity of vaccine specific antibodies present in 
the human serum correlates with how much serum derived antibody binds to vaccine-
derived antigen. Antibodies from human serum bound to antigen were detected and 
bound by goat anti-human IgG conjugated to horseradish peroxidase, followed by a 
colored TMB substrate solution. The binding of the goat anti-human IgG to the human 
antibodies in the well, followed by the catalysis of the color-change reaction of the TMB 
substrate by the horseradish peroxidase bound to the goat anti-human IgG, creates a color 
intensity proportional to the quantity of human IgG antibody titer found in the serum 
sample. Color intensity was measured by absorbance at 450nm and internal control serum 
samples were included in each plate. Pre- and post-vaccination serum samples from each 
subject were tested on the same plate.  
 
Statistics 
Data were analyzed using Graphpad Prism and 2-way ANOVA analysis.  
 RESULTS 
For each subject, ELISA antibody titer tests were used to measure IgG1, IgG2, and IgG 
Total as indicators of immune response. Antibody titer increased significantly from pre-
vaccination to post-vaccination for IgG1, 2, and Total (p < 0.0001), indicating a 
significant immune response to vaccination for both short and long term obese 
individuals, as expected. However, Two-Way ANOVA analysis revealed that there was 
no significant difference in antibody titer increase between the short-term obese and long 
term obese groups for IgG1 (p = .2615) or IgG Total (p = 0.0721), contrary to my 
hypothesis.  There was a significant difference in increase in IgG 2 antibody titer  (p = 
0.0147) between the short term and long-term obese subjects, with the long-term obese 
subjects showing greater increase in IgG 2 antibody titer after vaccination compared to 
the short-term obese group.  
 
Figure 1: Mean IgG1 antibody titer pre- and post-vaccination for short term obese (STO) 
and long term obese (LTO) individuals.  
 
 
Figure 2: Mean IgG 2 antibody titer pre- and post-vaccination for STO and LTO 
individuals.  
 
 
Figure 3: Mean total IgG antibody titers pre- and post-vaccination for STO and LTO 
individuals. 
Interesting observations were also seen from the graphs of IgG versus age for the 
following four categories: short term obesity pre-vaccination, short term obesity post-
vaccination, long term obesity pre-vaccination, and long term obesity post-vaccination. 
Short-term obese individuals had lower IgG 2 antibody titers at nearly all ages pre and 
post-vaccination compared to long-term obese individuals. Antibody titers for IgG 1 and 
IgG T exhibited more typical patterns of decline with age for short term obesity (pre and 
post-vaccination) and long term obesity post-vaccination. However, both IgG 1 and IgG 
Total exhibited the lowest antibody titer for young, long-term obese individuals pre-
vaccination, which then increased with age.  
 
 
Figure 4: IgG 1 antibody titer versus age pre- and post-vaccination for STO and LTO 
individuals.  
 Figure 5: IgG 2 antibody titer versus age pre- and post-vaccination for STO and LTO 
individuals.  
 
 
Figure 6: Total IgG antibody titer versus age pre- and post-vaccination for STO and LTO 
individuals. 
 
 
 
DISCUSSION 
Overall, long term obese individuals did not have a significantly poorer immune response 
to influenza vaccination when compared to short term obese individuals as measured by 
ELISA IgG antibody titer tests. However, an interesting trend shown in the graphs of IgG 
1 and IgG T versus age revealed that the lowest antibody titers existed among the 
youngest long term obese individuals. Contrary to the typical pattern of antibody titer 
decreasing as age increases, the opposite held true for the long term obese individuals: 
the IgG 1 and IgG T antibody titers both increased with age among this group. Subjects 
who were 60-70 years old exhibited higher IgG 1 and IgGT antibody titers than subjects 
20-40 years old. This surprising trend may reveal that the age of onset of obesity may be 
more impactful for immune response to influenza vaccine than the duration of obesity 
 
Data for IgG 3 showed no significant differences between the antibody titers for the LTO 
and STO groups. Several negative values indicated that the background for these readings 
may have been too high considering that IgG 3 constitutes only 5-10% of total IgG 
present in humans and is therefore expected to be present in low concentrations among 
both groups.  
 
The only statistically significant difference between the STO and LTO groups was 
exhibited in the IgG 2 antibody titers. The LTO individuals had higher IgG 2 antibody 
titers than the STO individuals. This outcome was unexpected due to the limited role of 
IgG 2 in the typical human response to influenza vaccine and because this finding was 
contrary to the original hypothesis that LTO individuals would have lower antibody titers 
than STO individuals.  
 
Because Immunoglobulin G is the major immunoglobulin found in serum and detection is 
typically indicative of prior infection or vaccination, I chose to use IgG as the major 
indicator of immune response to influenza vaccine. Of the four subclasses of IgG, IgG 1, 
3, and 4 are involved in the immune response to protein and polypeptide antigens and 
IgG 2 is involved in the immune response to carbohydrate or polysaccharide antigens.8 
ELISA results for IgG 1 and IgG Total showed the least error, likely due the quantity 
present as IgG 1 comprises 60 – 65% of total IgG. Results for IgG 3 showed a large 
amount of variation, and error had a greater impact because IgG 3 comprises only 5-10% 
of total IgG. Based on the results of ELISAs for IgG 3, I chose not to run ELISAs for IgG 
4 because it comprises less than 4% of total IgG and would have likely produced 
unreliable results due to error.9  
 
IgG 2, the second most abundant IgG subtype, was the only IgG subtype for which there 
was a statistically significant difference between the long term and short term obese 
groups. The long term obese subjects had a higher IgG 2 antibody titer than the short 
term obese subjects, representing an unexpected immune response both because I 
hypothesized that long term obesity would further repress the immune response, as well 
as because increased IgG 2 antibody titer is not a typical response to influenza virus, 
which has no carbohydrate components. This response is therefore indicative of some 
possible impairment in the immune response of long term obese individuals to influenza 
vaccine.  
 
Although there were few statistically significant differences shown between the antibody 
titers of the long term individuals and the short term individuals, the findings displayed in 
Figures 1 and 3 indicate that the age of onset of obesity may have greater implications on 
immune response to influenza vaccine than does that actual duration of obesity. Future 
research has the potential to explore these mechanisms, possibly by comparing obese 
individuals who became obese before the age of twenty with obese individuals who 
became obese after the age of forty rather than comparing two groups of individuals on 
the criteria of the duration of their obesity.  
 
Limitations 
This study contained several limitations related to the subject pool. The sample size was 
small and the number of individuals with ten years of available medical record data from 
which to extract BMI history was limited. Additionally, many of the short term obese 
individuals had been obese for five to nine years and many of the long term obese 
individuals had been obese for eleven to fifteen years, decreasing the obesity duration gap 
between the short term and long term obese groups. Many of the individuals classified as 
short term obese had been overweight (BMI between 25 and 29.9) for several years prior 
to reaching a BMI greater than 30.0 and therefore being classified as obese. Due to the 
relatively arbitrary nature of using BMI to characterize obesity, the long-term overweight 
individuals may have an immune response relatively similar to the long-term obese 
individuals, minimizing the differences in response between the two groups.  
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